Glaucoma Global Key Players - Alcon (Novartis), Santen, Pfizer, Otsuka, and Valeant Market Analysis & Forecast to 2026

Glaucoma

Overview

Glaucoma is the leading cause of irreversible vision loss, worldwide. The term glaucoma includes many different diseases, which are associated with differing risk factors, symptoms, treatment, and prognosis. All forms of glaucoma are characterized by the loss of the retinal ganglion cells and their axons that make up the optic nerve, which results in a cupping of the optic nerve head.

This leads to optic nerve damage and visual field loss. Raised intraocular pressure (IOP) is the primary risk factor for glaucoma, and progression of disease will normally stop if the IOP is lowered by 30-50%. Consequently, treatment options for glaucoma are developed around lowering the IOP. Although it is possible to slow the progression of glaucoma using current treatment options, it is not possible to reverse vision loss that has resulted from the disease.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/3090622-pharmapoint-glaucoma-global-drug-forecast-and-market-analysis-to-2026

Major Key Players

Alcon (Novartis)

Santen

Pfizer

Otsuka

Valeant

Ocular Therapeutix

Kowa Company

Senju Pharmaceutical

 

Glaucoma Industry Major Outlook

Most drugs prescribed for glaucoma can be placed into one of four drug classes. Prostaglandin analogues (PGAs) are generally used as a first-line treatment, with beta blockers (BBs), alpha adrenergic receptor agonists (AAs), and carbonic anhydrase inhibitors (CAIs) also frequently used, albeit generally as second-line therapies in combination with PGAs. Certain combinations of available drugs are marketed as part of fixed-dose combination (FDC) therapies. Cholinergic agonists, also known as miotics, can also be used for the treatment of glaucoma, although they are much less commonly prescribed compared with PGAs, BBs, AAs, and CAIs..  

Glaucoma - Competitive Analysis

Key players are making innovative developments in Glaucoma industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

 Overview of glaucoma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies. 
- Topline Glaucoma market revenue from 2016-2026. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included. 
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting glaucoma therapeutics sales in the 7MM. 
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products. 
- Analysis of the current and future market competition in the global CDI therapeutics and prophylactics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/3090622-pharmapoint-glaucoma-global-drug-forecast-and-market-analysis-to-2026

Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.

WISEGUY RESEARCH CONSULTANTS PVT LTD
Office No. 528, Amanora Chambers
Pune - 411028
Maharashtra, India

This release was published on openPR.